Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals-Photo via Shutterstock

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday.

The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a loss of 79 cents.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.